Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
- 9 November 2018
- journal article
- review article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 22 (2) , 195-205
Abstract
The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) differs from that of the primary tumor and is dynamic during tumor progression. The real-time and repeated characterization of this process via conventional solid tumor biopsies is challenging. Alternatively, circulating cell-free DNA (cfDNA) containing circulating tumor DNA (ctDNA) can be obtained from patient plasma using minimally disruptive blood draws and is amenable to sequential analysis. ctDNA has high overlap with the genomic sequences of biopsies from metastases and has the advantage of being representative of multiple metastases. The availability of techniques with high sensitivity and specificity, such as next-generation sequencing (NGS) and digital PCR, has greatly contributed to the development of the cfDNA field and enabled the detection of genomic alterations at low ctDNA fractions. In mCRPC, a number of clinically relevant genomic alterations have been tracked in ctDNA, including androgen receptor (AR) aberrations, which have been shown to be associated with an adverse outcome to novel antiandrogen therapies, and alterations in homologous recombination repair (HRR) genes, which have been associated with a response to PARP inhibitors. Several clinical applications have been proposed for cfDNA analysis, including its use as a prognostic tool, as a predictive biomarker, to monitor tumor response and to identify novel mechanisms of resistance. To date, the cfDNA analysis has provided interesting results, but there is an urgent need for these findings to be confirmed in prospective clinical trials.Keywords
Funding Information
- Prostate Cancer UK (PG12-49)
This publication has 94 references indexed in Scilit:
- Overcoming mutation-based resistance to antiandrogens with rational drug designeLife, 2013
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerNew England Journal of Medicine, 2013
- Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome SequencingScience Translational Medicine, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Clonal evolution in cancerNature, 2012
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate CancerCancer Cell, 2011
- Development of Personalized Tumor Biomarkers Using Massively Parallel SequencingScience Translational Medicine, 2010
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663Journal of Clinical Oncology, 2003